ID: ALA302067

Max Phase: Preclinical

Molecular Formula: C11H12N4O2

Molecular Weight: 232.24

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1ccc(CC(C(=O)O)c2c[nH]cn2)cn1

Standard InChI:  InChI=1S/C11H12N4O2/c12-10-2-1-7(4-14-10)3-8(11(16)17)9-5-13-6-15-9/h1-2,4-6,8H,3H2,(H2,12,14)(H,13,15)(H,16,17)

Standard InChI Key:  IFHWJTOFROTZBD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 232.24

Molecular Weight (Monoisotopic): 232.0960

AlogP: 0.80

#Rotatable Bonds: 4

Polar Surface Area: 104.89

Molecular Species: ACID

HBA: 4

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.52

CX Basic pKa: 7.67

CX LogP: -1.29

CX LogD: -1.33

Aromatic Rings: 2

Heavy Atoms: 17

QED Weighted: 0.72

Np Likeness Score: 0.40

References

1. Nantermet PG, Barrow JC, Lindsley SR, Young M, Mao SS, Carroll S, Bailey C, Bosserman M, Colussi D, McMasters DR, Vacca JP, Selnick HG..  (2004)  Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group.,  14  (9): [PMID:15080996] [10.1016/j.bmcl.2004.02.033]

2. Barrow JC, Nantermet PG, Stauffer SR, Ngo PL, Steinbeiser MA, Mao SS, Carroll SS, Bailey C, Colussi D, Bosserman M, Burlein C, Cook JJ, Sitko G, Tiller PR, Miller-Stein CM, Rose M, McMasters DR, Vacca JP, Selnick HG..  (2003)  Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.,  46  (25): [PMID:14640538] [10.1021/jm034141y]

3. Barrow JC, Nantermet PG, Stauffer SR, Ngo PL, Steinbeiser MA, Mao SS, Carroll SS, Bailey C, Colussi D, Bosserman M, Burlein C, Cook JJ, Sitko G, Tiller PR, Miller-Stein CM, Rose M, McMasters DR, Vacca JP, Selnick HG..  (2003)  Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.,  46  (25): [PMID:14640538] [10.1021/jm034141y]

4. Barrow JC, Nantermet PG, Stauffer SR, Ngo PL, Steinbeiser MA, Mao SS, Carroll SS, Bailey C, Colussi D, Bosserman M, Burlein C, Cook JJ, Sitko G, Tiller PR, Miller-Stein CM, Rose M, McMasters DR, Vacca JP, Selnick HG..  (2003)  Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.,  46  (25): [PMID:14640538] [10.1021/jm034141y]

5. Brink M, Dahlén A, Olsson T, Polla M, Svensson T..  (2014)  Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa).,  22  (7): [PMID:24588961] [10.1016/j.bmc.2014.02.010]

Source

Source(1):

• Scientific Literature